Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.54 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.49 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.49 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16926002 | 1.00 | NFE2L2 (0.54) | NFE2L2CYP1A1CYP1B1TRPM8RELA | |
| SCHEMBL14027834 | 0.87 | RELA (0.55) | NFE2L2CYP1B1TRPM8RELAPTGS1 | |
| SCHEMBL2605486 | 0.87 | RELA (0.55) | NFE2L2CYP1B1TRPM8RELAPTGS1 | |
| SCHEMBL14199696 | 0.87 | RELA (0.55) | NFE2L2CYP1B1TRPM8RELAPTGS1 | |
| SCHEMBL5494966 | 0.87 | RELA (0.55) | NFE2L2CYP1B1TRPM8RELAPTGS1 | |
| SCHEMBL16790468 | 0.87 | RELA (0.55) | NFE2L2CYP1B1TRPM8RELAPTGS1 | |
| SCHEMBL14003818 | 0.87 | RELA (0.55) | NFE2L2CYP1B1TRPM8RELAPTGS1 | |
| SCHEMBL10082096 | 0.87 | RELA (0.55) | NFE2L2CYP1B1TRPM8RELAPTGS1 | |
| SCHEMBL12763707 | 0.87 | RELA (0.55) | NFE2L2CYP1B1TRPM8RELAPTGS1 | |
| SCHEMBL10092966 | 0.87 | RELA (0.55) | NFE2L2CYP1B1TRPM8RELAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9507284-B2 | Electrophotographic photoreceptor, electrophotographic photoreceptor cartridge, image-forming apparatus, and triarylamine compound | MITSUBISHI CHEMICAL CORPORATION (JP) | 2016-11-29 | — | — | US | disclosed |
| US-20150205217-A1 | ELECTROPHOTOGRAPHIC PHOTORECEPTOR, ELECTROPHOTOGRAPHIC PHOTORECEPTOR CARTRIDGE, IMAGE-FORMING APPARATUS, AND TRIARYLAMINE COMPOUND | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150205217-A1 | ELECTROPHOTOGRAPHIC PHOTORECEPTOR, ELECTROPHOTOGRAPHIC PHOTORECEPTOR CARTRIDGE, IMAGE-FORMING APPARATUS, AND TRIARYLAMINE COMPOUND | ALDH1A2, SLC18A2, SLC1A2 | NFE2L2 522/4885CYP1A1 2010/4885CYP1B1 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.